Page 4 - Drug Controller General Of India

Covid-19: Indian sites await DCGI nod to restart Oxford vaccine trial

The Drug Controller General of India (DCGI) V G Somani will take a call after he receives data from the Data and Safety Monitoring Board (DSMB) in the UK as well as India

Abbott gets DCGI nod for once-a-day heart failure, angina treatment drug

Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks, Abbott said in a statement. This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added. The formulation has been developed at Abbott's innovation & development (I&D) centre in Mumbai, the statement said. "Adherence to therapy is a critical factor to maximize the overall health of people with chronic heart failure or chronic stable angina. We have used the best technology and science to develop this new dosage formulation," Abbott Regional Medical Director Balagopal Nair said. The convenient once-a-day formulation will help improve overall ...

Oxford Covid-19 vaccine trials in India: Serum Institute seeks DCGI nod

Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the UK showed it has an acceptable safety profile and homologous boosting increased antibody responses

Jenburkt Pharma launches Covid-19 drug Favipiravir at Rs 39 per tablet

The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely, much-needed therapeutic solution

Cipla gets DCGI approval to sell Covid-19 drug favipiravir in India

Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at 68 Indian rupees (91 cents) per 200 mg tablet

We want to price Covid-19 vaccine below Rs 1,000: Serum Institute CEO

Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222

FabiFlu cheaper than other drugs to treat Covid-19, claims Glenmark

The company further claimed that since favipiravir was an oral therapy, patients could be treated on an out-patient basis without incurring additional hospitalisation expenses

Glenmark defends pricing of Covid-19 drug FabiFlu, says it is economical

Glenmark also denies making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate Covid-19 patients

Jubilant Generics gets DCGI nod to manufacture Covid-19 drug Remdesivir

On June 21, Hetero and Cipla and on July 2 Mylan were given permission to manufacture and market the drug on the same conditions

Glenmark under fire for over pricing, 'misguided' claims of Covid-19 drug

NCP legislator Amol Kolhe's letter to Health Minister Harsh Vardhan triggers the DCGI to seek details from the Mumbai-based drugmaker

Glenmark gets DCGI notice over 'false claims', price of Covid drug FabiFlu

The 'subject' of the letter was stated as: "Regarding the false claims and pricing of tab FabiFlu 200 mg (favipiravir) by Glenmark Pharmaceuticals Limited, India"

Why vaccines can't be launched overnight

Under normal circumstances, the development of new vaccines and treatments could take 10-20 years

Pharma industry steps up to cure black marketing of Covid-19 drugs

Some firms are now considering starting their own distribution centres in major cities

Drug controller approves Biocon's psoriasis drug for emergency Covid-19 use

The firm presented the phase II clinical trial results to the drug regulator which were deliberated upon by the Subject Expert Committee of the DCGI's office

Mylan gets DGCI nod, to launch generic remdesivir at Rs 4,800 per vial

Mylan's version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic versions of the drug

Covaxin, ZyCov-D trails mark 'beginning of the end' of Covid-19: Scientist

The article has been published on the websites of the Press Information Bureau (PIB) and the Vigyan Prasar, which is a body under the ministry

Covid-19 crisis: Made-in-India remdesivir may come by end of June

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

Maharashtra may procure remdesivir from Bangladesh to treat Covid patients

State government to procure 10,000 vials for Rs 12 crore

Russia backing antiviral drug Avifavir for Covid fight good news for India

Avifavir, described by its developers in Russia as perhaps the most promising anti-Covid-19 drug in the world, is derived from Favipiravir.

Covid-19: Pune-based drug firm to export favipiravir to 18 countries

Favipiravir is under trial in many countries as a potential treatment for Covid-19